Suppression of the growth and invasion of human head and neck squamous cell carcinomas via regulating STAT3 signaling and the miR-21/β-catenin axis with HJC0152

Yu Wang, Sinan Wang, Yansheng Wu, Yu Ren, Zhaoqing Li, Xiaofeng Yao, Chao Zhang, Na Ye, Chao Jing, Jiabin Dong, Kailiang Zhang, Shanshan Sun, Minghui Zhao, Wenyu Guo, Xin Qu, Yu Qiao, Haiying Chen, Lingping Kong, Rui Jin, Xudong Wang & 4 others Lun Zhang, Jia Zhou, Qiang Shen, Xuan Zhou

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Signal transducer and activator of transcription 3 (STAT3) is involved in the tumor growth and metastasis of human head and neck squamous cell carcinoma (HNSCC) and is therefore a target with therapeutic potential. In this study, we show that HJC0152, a recently developed anticancer agent and a STAT3 signaling inhibitor, exhibits promising antitumor effects against HNSCC both in vitro and in vivo via inactivating STAT3 and downstream miR-21/β-catenin axis. HJC0152 treatment efficiently suppressed HNSCC cell proliferation, arrested the cell cycle at the G0-G1 phase, induced apoptosis, and reduced cell invasion in both SCC25 and CAL27 cell lines. Moreover, HJC0152 inhibited nuclear translocation of phosphorylated STAT3 at Tyr705 and decreased VHL/β-catenin signaling activity via regulation of miR-21. Loss of function of VHL remarkably compromised the antitumor effect of HJC0152 in both cell lines. In our SCC25-derived orthotopic mouse models, HJC0152 treatment significantly abrogated STAT3/β-catenin expression in vivo, leading to a global decrease of tumor growth and invasion. With its favorable aqueous solubility and oral bioavailability, HJC0152 holds the potential to be translated into the clinic as a promising therapeutic strategy for patients with HNSCC.

Original languageEnglish (US)
Pages (from-to)578-590
Number of pages13
JournalMolecular Cancer Therapeutics
Volume16
Issue number4
DOIs
StatePublished - Apr 1 2017

Fingerprint

Catenins
STAT3 Transcription Factor
Growth
Cell Line
Cell Cycle Resting Phase
G1 Phase
Therapeutics
Antineoplastic Agents
Solubility
Biological Availability
Neoplasms
Cell Cycle
Cell Proliferation
Carcinoma, squamous cell of head and neck
Apoptosis
Neoplasm Metastasis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Suppression of the growth and invasion of human head and neck squamous cell carcinomas via regulating STAT3 signaling and the miR-21/β-catenin axis with HJC0152. / Wang, Yu; Wang, Sinan; Wu, Yansheng; Ren, Yu; Li, Zhaoqing; Yao, Xiaofeng; Zhang, Chao; Ye, Na; Jing, Chao; Dong, Jiabin; Zhang, Kailiang; Sun, Shanshan; Zhao, Minghui; Guo, Wenyu; Qu, Xin; Qiao, Yu; Chen, Haiying; Kong, Lingping; Jin, Rui; Wang, Xudong; Zhang, Lun; Zhou, Jia; Shen, Qiang; Zhou, Xuan.

In: Molecular Cancer Therapeutics, Vol. 16, No. 4, 01.04.2017, p. 578-590.

Research output: Contribution to journalArticle

Wang, Y, Wang, S, Wu, Y, Ren, Y, Li, Z, Yao, X, Zhang, C, Ye, N, Jing, C, Dong, J, Zhang, K, Sun, S, Zhao, M, Guo, W, Qu, X, Qiao, Y, Chen, H, Kong, L, Jin, R, Wang, X, Zhang, L, Zhou, J, Shen, Q & Zhou, X 2017, 'Suppression of the growth and invasion of human head and neck squamous cell carcinomas via regulating STAT3 signaling and the miR-21/β-catenin axis with HJC0152', Molecular Cancer Therapeutics, vol. 16, no. 4, pp. 578-590. https://doi.org/10.1158/1535-7163.MCT-16-0606
Wang, Yu ; Wang, Sinan ; Wu, Yansheng ; Ren, Yu ; Li, Zhaoqing ; Yao, Xiaofeng ; Zhang, Chao ; Ye, Na ; Jing, Chao ; Dong, Jiabin ; Zhang, Kailiang ; Sun, Shanshan ; Zhao, Minghui ; Guo, Wenyu ; Qu, Xin ; Qiao, Yu ; Chen, Haiying ; Kong, Lingping ; Jin, Rui ; Wang, Xudong ; Zhang, Lun ; Zhou, Jia ; Shen, Qiang ; Zhou, Xuan. / Suppression of the growth and invasion of human head and neck squamous cell carcinomas via regulating STAT3 signaling and the miR-21/β-catenin axis with HJC0152. In: Molecular Cancer Therapeutics. 2017 ; Vol. 16, No. 4. pp. 578-590.
@article{ff8d9968e6d144228fd1c4c636bffb8e,
title = "Suppression of the growth and invasion of human head and neck squamous cell carcinomas via regulating STAT3 signaling and the miR-21/β-catenin axis with HJC0152",
abstract = "Signal transducer and activator of transcription 3 (STAT3) is involved in the tumor growth and metastasis of human head and neck squamous cell carcinoma (HNSCC) and is therefore a target with therapeutic potential. In this study, we show that HJC0152, a recently developed anticancer agent and a STAT3 signaling inhibitor, exhibits promising antitumor effects against HNSCC both in vitro and in vivo via inactivating STAT3 and downstream miR-21/β-catenin axis. HJC0152 treatment efficiently suppressed HNSCC cell proliferation, arrested the cell cycle at the G0-G1 phase, induced apoptosis, and reduced cell invasion in both SCC25 and CAL27 cell lines. Moreover, HJC0152 inhibited nuclear translocation of phosphorylated STAT3 at Tyr705 and decreased VHL/β-catenin signaling activity via regulation of miR-21. Loss of function of VHL remarkably compromised the antitumor effect of HJC0152 in both cell lines. In our SCC25-derived orthotopic mouse models, HJC0152 treatment significantly abrogated STAT3/β-catenin expression in vivo, leading to a global decrease of tumor growth and invasion. With its favorable aqueous solubility and oral bioavailability, HJC0152 holds the potential to be translated into the clinic as a promising therapeutic strategy for patients with HNSCC.",
author = "Yu Wang and Sinan Wang and Yansheng Wu and Yu Ren and Zhaoqing Li and Xiaofeng Yao and Chao Zhang and Na Ye and Chao Jing and Jiabin Dong and Kailiang Zhang and Shanshan Sun and Minghui Zhao and Wenyu Guo and Xin Qu and Yu Qiao and Haiying Chen and Lingping Kong and Rui Jin and Xudong Wang and Lun Zhang and Jia Zhou and Qiang Shen and Xuan Zhou",
year = "2017",
month = "4",
day = "1",
doi = "10.1158/1535-7163.MCT-16-0606",
language = "English (US)",
volume = "16",
pages = "578--590",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Suppression of the growth and invasion of human head and neck squamous cell carcinomas via regulating STAT3 signaling and the miR-21/β-catenin axis with HJC0152

AU - Wang, Yu

AU - Wang, Sinan

AU - Wu, Yansheng

AU - Ren, Yu

AU - Li, Zhaoqing

AU - Yao, Xiaofeng

AU - Zhang, Chao

AU - Ye, Na

AU - Jing, Chao

AU - Dong, Jiabin

AU - Zhang, Kailiang

AU - Sun, Shanshan

AU - Zhao, Minghui

AU - Guo, Wenyu

AU - Qu, Xin

AU - Qiao, Yu

AU - Chen, Haiying

AU - Kong, Lingping

AU - Jin, Rui

AU - Wang, Xudong

AU - Zhang, Lun

AU - Zhou, Jia

AU - Shen, Qiang

AU - Zhou, Xuan

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Signal transducer and activator of transcription 3 (STAT3) is involved in the tumor growth and metastasis of human head and neck squamous cell carcinoma (HNSCC) and is therefore a target with therapeutic potential. In this study, we show that HJC0152, a recently developed anticancer agent and a STAT3 signaling inhibitor, exhibits promising antitumor effects against HNSCC both in vitro and in vivo via inactivating STAT3 and downstream miR-21/β-catenin axis. HJC0152 treatment efficiently suppressed HNSCC cell proliferation, arrested the cell cycle at the G0-G1 phase, induced apoptosis, and reduced cell invasion in both SCC25 and CAL27 cell lines. Moreover, HJC0152 inhibited nuclear translocation of phosphorylated STAT3 at Tyr705 and decreased VHL/β-catenin signaling activity via regulation of miR-21. Loss of function of VHL remarkably compromised the antitumor effect of HJC0152 in both cell lines. In our SCC25-derived orthotopic mouse models, HJC0152 treatment significantly abrogated STAT3/β-catenin expression in vivo, leading to a global decrease of tumor growth and invasion. With its favorable aqueous solubility and oral bioavailability, HJC0152 holds the potential to be translated into the clinic as a promising therapeutic strategy for patients with HNSCC.

AB - Signal transducer and activator of transcription 3 (STAT3) is involved in the tumor growth and metastasis of human head and neck squamous cell carcinoma (HNSCC) and is therefore a target with therapeutic potential. In this study, we show that HJC0152, a recently developed anticancer agent and a STAT3 signaling inhibitor, exhibits promising antitumor effects against HNSCC both in vitro and in vivo via inactivating STAT3 and downstream miR-21/β-catenin axis. HJC0152 treatment efficiently suppressed HNSCC cell proliferation, arrested the cell cycle at the G0-G1 phase, induced apoptosis, and reduced cell invasion in both SCC25 and CAL27 cell lines. Moreover, HJC0152 inhibited nuclear translocation of phosphorylated STAT3 at Tyr705 and decreased VHL/β-catenin signaling activity via regulation of miR-21. Loss of function of VHL remarkably compromised the antitumor effect of HJC0152 in both cell lines. In our SCC25-derived orthotopic mouse models, HJC0152 treatment significantly abrogated STAT3/β-catenin expression in vivo, leading to a global decrease of tumor growth and invasion. With its favorable aqueous solubility and oral bioavailability, HJC0152 holds the potential to be translated into the clinic as a promising therapeutic strategy for patients with HNSCC.

UR - http://www.scopus.com/inward/record.url?scp=85017031202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017031202&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-16-0606

DO - 10.1158/1535-7163.MCT-16-0606

M3 - Article

VL - 16

SP - 578

EP - 590

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 4

ER -